arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Summit Therapeutics Inc.

SMMT

$13.96 ▲ +0.42 (+3.06%) at close

9 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Summit Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $10.4B

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC None

FCF / Share $-0.43 ↘

Trailing P/E —

Price / Book 16.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-1.08B

↓ -387.8% —

FCF / Share Free cash flow per share

$-0.43

↓ -118.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jan 31, 2019 10-K ↗	FY 2017 Jan 31, 2018 10-K ↗
Revenue Growth YoY (%)	—	—	N/M	-61.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-863%)	110.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1279%)	15.7% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+97%)	-98.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1334%)	—	—
EPS Growth YoY (%)	-364.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	68.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-141.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	38.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	11.8% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	14.6% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—
Net Income Growth YoY (%)	-387.8% Weak ↓ Weak Declining Year-over-year change in net income	64.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-680.5% Weak ↓ Weak Declining Year-over-year change in net income	11.1% Fair ↑ Fair Improving Year-over-year change in net income	-68.1% Weak Weak Year-over-year change in net income	-80.9% Weak Weak Year-over-year change in net income	N/M	—	—
FCF Growth YoY (%)	-118.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	-59.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	43.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	60.6% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	20.7% Good ↓ Good Declining Year-over-year change in free cash flow	-9.3% Weak Weak Year-over-year change in free cash flow	69.0% Excellent Excellent Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	—	—	—	-1.7% Weak Weak Compound annual revenue growth over 3 years	-68.4% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jan 31, 2019 10-K ↗	FY 2017 Jan 31, 2018 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	9.4% Caution Caution Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-37%)	—
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	0.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-19.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	19.0% Good Good Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+59%)	—
FCF Margin (%) (%)	—	—	—	—	—	—	—	-61.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.30x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.13x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	-3.24x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jan 31, 2019 10-K ↗	FY 2017 Jan 31, 2018 10-K ↗
Return on Invested Capital (%)	—	-45.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-619.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-81.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-66.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	11.2% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	—	-51.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-300.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-76.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-51.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-28.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-163.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1192%)	-56.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-480%)	—	-62.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-515%)	-106.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-809%)	-66.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-542%)	-36.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-346%)	18.9% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+26%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jan 31, 2019 10-K ↗	FY 2017 Jan 31, 2018 10-K ↗
Interest Coverage (x)	—	-25.66x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-57.24x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-16.38x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-356.14x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-208.60x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-94.41x Weak Weak Operating income divided by interest expense Optimal: > 5x	8.69x Good Good Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-225.27M	$-104.86M	$-71.42M	$-348.61M	$-71.79M	—	$-63.84M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jan 31, 2019 10-K ↗	FY 2017 Jan 31, 2018 10-K ↗
Revenue per Share (USD)	—	$0.00	$0.00	$0.00	$0.01	$0.01	$0.02	$3.33	—
Basic EPS, GAAP (USD)	$-1.44	$-0.31	$-0.99	$-0.41	$-0.67	$-0.76	$-0.89	$0.63	—
Free Cash Flow per Share (USD)	$-0.43	$-0.20	$-0.12	$-0.22	$-0.55	$-0.70	$-0.64	$-2.06	—
Book Value per Share (USD)	$0.85	$0.53	$0.11	$0.60	$0.85	$0.24	$1.17	$3.36	—
Tangible Book Value per Share (USD)	$0.85	$0.52	$0.11	$0.59	$0.83	$0.23	$1.14	$3.25	—
Basic Weighted Avg Shares (shares)	747.70M	718.54M	619.65M	193.34M	131.71M	69.52M	32.83M	17.14M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jan 31, 2019 10-K ↗	FY 2017 Jan 31, 2018 10-K ↗
Working Capital (USD)	$647.31M	$382.02M	$169.31M	$617.93M	$71.69M	$67.78M	$65.86M	—	—
Total Equity (USD)	$658.86M	$388.75M	$77.69M	$126.65M	$83.28M	$79.45M	$78.86M	$57.59M	$-3.59M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Jan 31, 2019 10-K ↗	FY 2017 Jan 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	—	$0.00	$0.00	$705.00K	$1.81M	$860.00K	$743.00K	$57.09M	—
Depreciation Expense (USD)	$146.00K	$89.00K	$198.00K	$349.00K	$330.00K	$302.00K	$321.00K	$409.00K	—
Net Income, GAAP (USD)	$-1.08B	$-221.31M	$-614.93M	$-78.78M	$-88.60M	$-52.70M	$-29.13M	$10.87M	—
Operating Cash Flow (USD)	$-322.93M	$-142.11M	$-76.76M	$-41.58M	$-72.59M	$-48.11M	$-20.76M	$-35.11M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters

Summit Therapeutics Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SMMT with peers